Shaoheng Ni
Overview
Explore the profile of Shaoheng Ni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, et al.
PLoS One
. 2008 Jun;
3(6):e2409.
PMID: 18560559
Background: Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and less toxic than current therapies due to the agents selective growth and amplification...
2.
Tuve S, Chen B, Liu Y, Cheng T, Toure P, Sow P, et al.
Cancer Res
. 2007 Jun;
67(12):5929-39.
PMID: 17575163
Accumulating data indicate that tumor-infiltrating regulatory T cells (Treg) are present in human tumors and locally suppress antitumor immune cells. In this study, we found an increased Treg/CD8 ratio in...
3.
Stone D, Liu Y, Shayakhmetov D, Li Z, Ni S, Lieber A
J Virol
. 2007 Feb;
81(9):4866-71.
PMID: 17301138
Intravenous (i.v.) delivery of recombinant adenovirus serotype 5 (Ad5) vectors for gene therapy is hindered by safety and efficacy problems. We have discovered a new pathway involved in unspecific Ad5...
4.
Strauss R, Huser A, Ni S, Tuve S, Kiviat N, Sow P, et al.
Mol Ther
. 2006 Dec;
15(1):193-202.
PMID: 17164791
Baculovirus vectors are able to transduce a large variety of mammalian cell types and express transgenes placed under the control of heterologous promoters. In this study, we evaluated the potential...
5.
Parker A, Waddington S, Nicol C, Shayakhmetov D, Buckley S, Denby L, et al.
Blood
. 2006 Jun;
108(8):2554-61.
PMID: 16788098
Upon local delivery, adenovirus (Ad) serotype 5 viruses use the coxsackie and Ad receptor (CAR) for cell binding and alpha(v) integrins for internalization. When administered systemically, however, their role in...
6.
DiPaolo N, Ni S, Gaggar A, Strauss R, Tuve S, Li Z, et al.
Mol Ther
. 2006 Feb;
13(4):756-65.
PMID: 16461009
In contrast to commonly used serotype 5-based adenovirus (Ad) vectors, Ad's containing fibers derived from B-group serotype 35 (Ad5/35) efficiently transduce human DCs ex vivo and appear to target antigen-presenting...
7.
Di Paolo N, Tuve S, Ni S, Hellstrom K, Hellstrom I, Lieber A
Cancer Res
. 2006 Jan;
66(2):960-9.
PMID: 16424031
Heat shock proteins such as gp96 have the ability to chaperone peptides and activate antigen-presenting cells. In this study, we tested whether adenovirus-mediated overexpression of secreted or membrane-associated forms of...
8.
Ni S, Bernt K, Gaggar A, Li Z, Kiem H, Lieber A
Hum Gene Ther
. 2005 Jun;
16(6):664-77.
PMID: 15960598
Vectors containing group B adenovirus (Ad) fibers are able to efficiently transduce gene therapy targets that are refractory to infection with standard Ad serotype 5 (Ad5) vectors, including malignant tumor...
9.
Shayakhmetov D, Gaggar A, Ni S, Li Z, Lieber A
J Virol
. 2005 May;
79(12):7478-91.
PMID: 15919903
Adenoviruses (Ad) are efficient vehicles for gene delivery in vitro and in vivo. Therefore, they are a promising tool in gene therapy, particularly in the treatment of cancer and cardiovascular...
10.
Shayakhmetov D, Li Z, Ni S, Lieber A
J Immunol
. 2005 May;
174(11):7310-9.
PMID: 15905578
The safety of gene therapy vectors is a major concern when novel viral or nonviral therapeutics are proposed for applications in humans. Adenovirus (Ad) vectors have been extensively used as...